BACKGROUND: Western randomized trials and prospective cohorts in resource-limited settings have proven virological success with stavudine-based highly active antiretroviral therapy. However, stavudine is no longer recommended in first-line treatments in these two settings due to its intrinsic toxicities and side effects. Yet it remains a cornerstone of treatment in resource-limited settings, due to lack of alternatives and its availability in generic fixed-dose combinations. OBJECTIVE: To review the toxic effects of stavudine and their prevention and management strategies, especially in resource-limited settings. METHODS: Data from clinical and pharmacological trials in Western countries, as well as prospective cohorts in resource-limited settings, were reviewed. CONCLUSION: Initiating or switching to less toxic nucleoside analogues whenever possible, or lowering stavudine doses to 30 mg b.i.d., is strongly recommended.
BACKGROUND: Western randomized trials and prospective cohorts in resource-limited settings have proven virological success with stavudine-based highly active antiretroviral therapy. However, stavudine is no longer recommended in first-line treatments in these two settings due to its intrinsic toxicities and side effects. Yet it remains a cornerstone of treatment in resource-limited settings, due to lack of alternatives and its availability in generic fixed-dose combinations. OBJECTIVE: To review the toxic effects of stavudine and their prevention and management strategies, especially in resource-limited settings. METHODS: Data from clinical and pharmacological trials in Western countries, as well as prospective cohorts in resource-limited settings, were reviewed. CONCLUSION: Initiating or switching to less toxic nucleoside analogues whenever possible, or lowering stavudine doses to 30 mg b.i.d., is strongly recommended.
Authors: Nicole L De La Mata; Nagalingeswaran Kumarasamy; Vohith Khol; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Nicolas Durier; Matthew Law Journal: Antivir Ther Date: 2016-02-10
Authors: Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng Journal: Antivir Ther Date: 2018
Authors: Andrew Ratsela; Michael Polis; Sibongiseni Dhlomo; Sean Emery; Greg Grandits; Paul Khabo; Thandeka Khanyile; Stephanus Komati; James D Neaton; Lionel Chris David Naidoo; Daphne Magongoa; Duma Qolohle Journal: J Infect Dis Date: 2010-10-13 Impact factor: 5.226
Authors: Wei-Ti Chen; Cheng-Shi Shiu; Joyce P Yang; Jane M Simoni; Karen I Fredriksen-Goldsen; Tony Szu-Hsien Lee; Hongxin Zhao Journal: J AIDS Clin Res Date: 2013-06-29
Authors: Herbert C Duber; Emily Dansereau; Samuel H Masters; Jane Achan; Roy Burstein; Brendan DeCenso; Anne Gasasira; Gloria Ikilezi; Caroline Kisia; Felix Masiye; Pamela Njuguna; Thomas Odeny; Emelda Okiro; D Allen Roberts; Emmanuela Gakidou Journal: PLoS One Date: 2015-03-25 Impact factor: 3.240
Authors: Menard Chihana; Sian Floyd; Anna Molesworth; Amelia C Crampin; Ndoliwe Kayuni; Alison Price; Basia Zaba; Andreas Jahn; Hazzie Mvula; Albert Dube; Bagrey Ngwira; Judith R Glynn; Neil French Journal: Trop Med Int Health Date: 2012-08 Impact factor: 2.622
Authors: G Pillai; G Davies; P Denti; J-L Steimer; H McIlleron; S Zvada; E Chigutsa; E Ngaimisi; F Mirza; B Tadmor; N H G Holford Journal: CPT Pharmacometrics Syst Pharmacol Date: 2013-08-28